Two Sigma Advisers LP Buys 25,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Two Sigma Advisers LP lifted its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 9.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 298,700 shares of the biopharmaceutical company's stock after acquiring an additional 25,000 shares during the period. Two Sigma Advisers LP owned approximately 0.39% of Xenon Pharmaceuticals worth $11,709,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Two Sigma Investments LP lifted its stake in Xenon Pharmaceuticals by 12.2% in the 4th quarter. Two Sigma Investments LP now owns 273,352 shares of the biopharmaceutical company's stock worth $10,715,000 after purchasing an additional 29,773 shares in the last quarter. Tema Etfs LLC bought a new stake in Xenon Pharmaceuticals during the fourth quarter valued at $240,000. Stempoint Capital LP purchased a new position in Xenon Pharmaceuticals during the fourth quarter worth about $14,733,000. Sphera Funds Management LTD. bought a new position in Xenon Pharmaceuticals in the 4th quarter worth about $2,042,000. Finally, Polar Capital Holdings Plc boosted its position in shares of Xenon Pharmaceuticals by 10.3% during the 4th quarter. Polar Capital Holdings Plc now owns 2,697,657 shares of the biopharmaceutical company's stock valued at $105,748,000 after acquiring an additional 253,012 shares during the last quarter. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Down 0.4%

Shares of Xenon Pharmaceuticals stock traded down $0.11 on Tuesday, hitting $29.64. The stock had a trading volume of 720,466 shares, compared to its average volume of 730,095. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -10.50 and a beta of 1.21. The stock's 50-day simple moving average is $33.52 and its two-hundred day simple moving average is $37.35. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.07. The firm had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same period last year, the company posted ($0.62) earnings per share. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on XENE. Needham & Company LLC decreased their price objective on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Wells Fargo & Company dropped their price objective on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "buy" rating and a $67.00 target price for the company. Finally, Chardan Capital reaffirmed a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $54.82.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.